期刊
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
卷 179, 期 4, 页码 307-312出版社
AMER THORACIC SOC
DOI: 10.1164/rccm.200807-1082OC
关键词
Lofgren's syndrome; sarcoidosis; HLA
资金
- The Swed sh Heart-Lung Foundation
- The King Oscar II Jubilee Foundation
- Swedish Medical Research Council
- The Mats Kleberg Foundation
- Karolinska Institutet
- Stockholm County Council
- Torsten and Ragnar Soderbergs Foundation
Rationale Sarcoidosis may consist of a number of distinct disease entities, one of which could be Lofgren's syndrome. Patients with Lofgren's syndrome have an acute onset of erythema nodosum (EN) and/or perarticular inflammation or arthritis of the ankles, with bilateral hilar lymphadenopathy (and in some cases parenchymal Infiltrates) and usually fever. There is a known association between HLA-DRB1*03 and Lofgren's syndrome. Objectives: To Investigate whether human leukocyte antigen type Influences clinical manifestations, Including the disease course In Lofgren's syndrome. Methods: We clinically characterized and HLA-DRB1 typed 301 patients with Lofgren's syndrome. A total of 275 of the patients were followed for more than 2 years and classified as having a non-resolving or a resolving disease. Measurements and Main Results: Almost every DRB1*03-positive patient had a resolving disease within 2 years, and 49% of the DRB1*03-negative patients developed a nonresolving disease. Mucosal granulomas were identified significantly more often in DRB1*03-negative patients. Among DRB1*03-negative patients who were treated with oral steroids at disease onset, 80% developed a nonresolving disease. Conclusions: Patients with Lofgren's syndrome have a different disease course depending on whether they are DRB1*03 positive or not. This observation has clinical implications, and by comparing DRB1*03-positive and DRB1*03-negative patients with Lofgren's syndrome, we can search for additional markers of importance for developing a resolving or a nonresolving disease, respectively.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据